孙昕

[摘要] 目的 探究在2型糖尿病患者治療过程中将二甲双胍和瑞格列奈进行应用的临床效果。方法 选取200例2型糖尿病患者，患者均为2018年7月—2019年7月期间在该院就诊的患者，将所有患者随机分为两组，其中一组给予瑞格列奈进行治疗，命名为对照组，例数为100例，另一组则采用瑞格列奈联合二甲双胍进行治疗，将其命名为实验组，人数为100例，对不同方法的干预效果进行分析比较。结果 在给予患者治疗干预前，两组患者的糖化血红蛋白，空腹血糖和餐后2 h血糖量差异无统计学意义（P>0.05）。在给予治疗干预后，实验组患者的空腹血糖量为（6.33±1.20）mmol/L，餐后2 h血糖量为（7.45±1.85）mmol/L，糖化血红蛋白量为（7.09±1.44）%，在与对照组患者进行比较的情况下，实验组患者的血糖情况更好，对其组间数据进行比较，差异有统计学意义（P<0.05）。而且实验组患者的血糖达标时间所对应的瑞格列奈平均用量更少，差异有统计学意义（P<0.05）。但实验组患者所对应的不良反应发生率明显高于对照组。结论 给予2型糖尿病患者瑞格列奈联合二甲双胍进行治疗，其效果显著，可将患者血糖进行有效控制，同时缩短患者的治疗时间，减少瑞格列奈的用量，但是在使用过程中，其所对应的不良反应较多，能够控制在一定范围内。

[关键词] 二甲双胍;瑞格列奈;初诊;2型糖尿病;治疗效果

[中图分类号] R587.1          [文献标识码] A          [文章编号] 1672-4062（2020）06（a）-0054-03

[Abstract] Objective To explore the clinical effect of applying metformin and repaglinide in the treatment of patients with type 2 diabetes. Methods 200 patients with type 2 diabetes were selected， all patients were in the hospital from July 2018 to July 2019， and all patients were randomly divided into two groups， one of which was given repaglinide for treatment， named as the control group， the number of people was 100， and the other group was treated with repaglinide combined with metformin， named as the experimental group， with a number of 100 people. The intervention effects of different methods were analyzed and compared. Results Before the treatment intervention was given to the patients， the difference in glycated hemoglobin， fasting blood glucose and 2 h postprandial blood glucose between the two groups of patients was small， the difference was  not statistically significant（P>0.05）， with no statistical significance. After treatment intervention， the fasting blood glucose of the experimental group was （6.33±1.20）mmol/L， the blood glucose 2 h after the meal was （7.45±1.85）mmol/L， and the amount of glycated hemoglobin was （7.09±1.44）%， In the case of comparison with the control group， the blood glucose of the experimental group is better. Comparing the data between the groups has statistical significance（P<0.05）. In addition， the average dose of repaglinide corresponding to the time of reaching the blood glucose standard in the experimental group was less， and the data between the groups was statistically significant（P<0.05）. However， the incidence of adverse reactions corresponding to patients in the experimental group was significantly higher than that in the control group. Conclusion The treatment of type 2 diabetes patients with repaglinide combined with metformin has a significant effect， which can effectively control the patient's blood glucose， and at the same time shorten the patient's treatment time and reduce the amount of repaglinide， but in the process of use， corresponding to many adverse reactions， it can be controlled within a certain range.

[Key words] Metformin; Repaglinide; Initial diagnosis; Type 2 diabetes; Treatment effect

据相关数据结果显示，糖尿病患者中有90%以上为2型糖尿病患者，其发病率逐年升高，从其目前的实际发展情况来看，2型糖尿病的发病率已经逐渐趋于年轻化，对青年患者的生活质量和生命健康造成了严重的不良影响，需临床加强对此问题的重视程度[1]。就2型糖尿病来说，导致其发生的主要原因为胰岛素抵抗，临床主要采用瑞格列奈进行干预，其能够实现对胰岛β细胞分泌的刺激，将患者的血糖水平进行降低。根据近些年的研究结果来看，瑞格列奈与二甲双胍进行联合使用对2型糖尿病进行治疗，其应用效果显著。该研……